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subjects with a50% reduction in bleeding events, the incremental cost-effective-
ness ratio in the prophylaxis vs. on demand period was US$ 77,067 per bleeding
event avoided. CONCLUSIONS: Cost-effectiveness ratios are within the commonly
accepted willingness-to-pay threshold. The incremental cost-effectiveness ratio
noticeably was more favorable in responders, which is totally attributable to the
marked difference in effectiveness. Moreover the Incremental cost per bleed
avoided during prophylactic period suggest prophylaxis to be more cost effective in
children, who could derive the greatest benefit in terms of joint disease and long-
term disability.
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OBJECTIVES: Invasive fungal infections (IFIs) have emerged as the major infection-
related cause of morbidity and mortality in patients undergoing hematopoietic
stem cell transplantations (HSCT). Ullmann et al published a RCT in allogeneic
HSCT recipients with grade 2–4 or extensive chronic GVHD that compared the
efficacy of posaconazole and fluconazole in the prevention of IFIs. Posaconazole
was shown to be as effective as fluconazole in preventing IFIs (5.3% vs. 9.0%) and
reduced IFI-related mortality (2.7% vs. 8.0%). We evaluated posaconazole cost-ef-
fectiveness from the Turkish health care system perspective. METHODS: A trial-
based decision-tree model was developed. The probabilities of experiencing an IFI,
IFI-related death, and death from other causes over 112 days post treatment were
provided from Ullmann trial. The model was extended to a lifetime horizon, in
which survival within the initial two years was based on the Ullmann trial and
survival beyond two years was based on adjustment of national life tables by stan-
dardize mortality rates obtained from literature. IFI-related costs were provided
from local literature. The model was used to estimate costs, life-years saved (LYS),
and the incremental cost-effectiveness ratio (ICER) of posaconazole vs. fluconazole
(year 2012). RESULTS: Posaconazole treatment appeared to be more effective with
increased LYS (3.90 vs. 3.67) however, more costly (32,717 USD vs. 31,298 USD) than
the alternative over a lifetime horizon. The ICER of posaconazole was 6,373 USD/
LYS compared to fluconazole. Univariate sensitivity analysis was conducted to
assess the effects of parameter uncertainty, particularly concerning treatment ef-
ficacy and long-term mortality. With almost all assumptions that were analyzed,
posaconazole ICER was well below the national gross domestic product per capita
per LYS threshold (10,444 USD/LYS). CONCLUSIONS: Posaconazole appeared to be
cost-effective vs. fluconazole in the prophylaxis of IFIs among patients with GVHD
undergoing allogeneic HSCT.
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OBJECTIVES: To assess the costs and outcomes of parecoxib used in combination
with opioids vs. opioids alone in the post-operative management of surgical pa-
tients in Greece. METHODS: A model comparing parecoxib plus opioid treatment,
to opioids alone during the first three days post-surgery was developed. Clinical
efficacy was based on a phase-III randomized, double-blind clinical trial that also
provided the frequencies of occurrence of clinically meaningful opioid-related ad-
verse events (CMEs) for both treatment arms. Resource use associated with each
CME was elicited via strictly structured questionnaire based interviews to a panel
of experts (surgeons and anesthesiologists). Cost calculations followed a third
party payer perspective (Euros, 2012). Treatment effectiveness was calculated in
Summed Pain Intensity scores (SPI). RESULTS: According to the clinical trial, pa-
tients under parecoxib plus opioids had lower pain scores (SPI 59.20 vs. 80.80) and
fewer CMEs (0.62 vs. 1.04 per patient) compared to opioids alone, for a 3-day period.
This led to a full offset of the excess cost of the addition of parecoxib and to
potential savings of 858€ (total cost per patient: 819.08 vs. 1,677.08, respectively).
Savings were mainly attributable to decreased CMEs, reductions in ICU and general
ward bed-days as well as to reduced physician and nurse time. Results were sen-
sitive with regards to probabilities of occurrence or co-occurrence of CMEs (2
CMEs occurring simultaneously), although the above was of limited impact. Med-
ication costs had a minimal impact on the results of the sensitivity analysis. Ex-
tending the model cycle to 5-days post-operatively was associated with additional
savings of 1,139.9€ per patient, compared to opioid use alone (total cost per patient:
1,063.2 vs. 2,203.1 respectively). CONCLUSIONS: Parecoxib can be a valuable addi-
tion to opioid treatment for post operative pain, improving pain relief, reducing the
probabilities of CME occurrence and lowering overall costs of treatment.
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OBJECTIVES: Pharmacoeconomic aspects of application of dexketoprofen trometa-
mol in routine clinical practice in Russia remain unclear. The aim of our research is
comparative pharmacoeconomic analysis of administration of dexketoprofen tro-
metamol in reduction of acute post-traumatic pain. METHODS: The estimation of
pain relief strategies with dexketoprofen and diclofenac was performed by a cost-
effectiveness analysis based on modeling method. We have calculated the costs of
treatment for pain syndrome in injuries of lower extremities in two groups of 100
patients, who received dexketoprofen or diclofenac. The choice of diclofenac was
motivated by the fact that it is the most frequently prescribed NSAID included into
the National Essential Drug List. The main efficiency measure was the level of
analgesia achieved within one hour after administration of a medication estimated
using Visual Analog Scale (VAS). Only direct costs of pain syndrome relief were
included in cost analysis in our model. RESULTS: The costs of therapy in diclofenac
and dexketoprofen groups were 1033.0 RUB and 1611.1 RUB, respectively. Final
cost-efficiency ratio was 39.73 RUB per unit in diclofenac, and 20.92 in dexketopro-
fen group. Incremental cost-effectiveness ratio (11.34 RUB/unit) revealed that treat-
ment with dexketoprofen trometamol demands additional funding for signifi-
cantly greater effect compared to diclofenac. Sensitivity analyses indicated these
results to be robust. CONCLUSIONS: The results of our study suggest that the
application of dexketoprofen trometamol has the best cost-effectivness in acute
posttraumatic syndrome compared to traditionally prescribed diclofenac.
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OBJECTIVES: To perform an economic evaluation of OST in Greece. Individuals
wishing to participate in OST are increasing, since only 4,046 opioid-dependent
persons were participating in OST programs in 2008, whilst 5,386 who were willing
to receive OST were on the waiting list for treatment, with a mean waiting-list time
of 6 years.METHODS:Data were gathered from theK and EKTEPN, the Greek
REITOX (European Information Network on Drugs and Drug Addiction) Focal Point
of the European Monitoring Centre for Drugs and Drug Addiction .The total number
of patients included in the analysis was 4046 . Statistical tests were used to test the
homogeneity between treatment programs as well as among geographical areas.
Cost-minimization and cost-effectiveness analyses were conducted to compare
methadone and buprenorphine monotherapy with buprenorphine–naloxone. A
budget-impact analysis was undertaken in order to estimate the potential costs
and savings that could be gained from the expansion of OST programs in Greece.
Deterministic and probabilistic sensitivity analyses were performed. To represent
the output uncertainty from probabilistic sensitivity analysis scatterplots of 2000
simulated ICERs were produced on the cost-effectiveness plane as well as cost-
effectiveness acceptability curves. RESULTS: Cost-minimization analysis pre-
dicted that buprenorphine monotherapy is more costly than buprenorphine–nal-
oxone. Cost-effectiveness analyses demonstrated that buprenorphine–naloxone
was the dominating therapy in terms of mortality avoidance and completion of
treatment. In comparison to methadone, buprenorphine–naloxone reduced the
mean cost by 49%; increased by 1.5-fold the percentage of participants complet-
ing their treatment; and reduced by2.5-fold the percentage of deaths. Sensitivity
analyses did not reverse the findings. CONCLUSIONS: Our findings demonstrated
that switching to buprenorphine-naloxone treatment would result in significant
savings, reduce waiting lists and increase access to OST. The introduction of phar-
macoeconomic studies in Greece would support rational decision-making in an era
of economic recession and uncertainty.
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OBJECTIVES: Early diagnosis and aggressive treatment is crucial in rheumatoid
arthritis to prevent disease development, joint destruction and cardiovascular dis-
ease, which start within first 2 years of disease. This study aims to perform cost-
effectiveness analysis of etanercept in early rheumatoid arthritis (ERA) treatment,
defined as disease duration from 3 months to 2 years, from the public payer per-
spective in Brazil. METHODS: A decision model was developed to simulate ERA
evolution after treatment with etanercept(50mg/week)methotrexate (ETNMTX)
or methotrexate (MTX) as first-line therapies and their associated direct costs over
a 5-year time horizon. An initial decision tree estimated the number of patients
entering Markov model in the following health states: ‘remission’, ‘non-remission’,
‘discontinuation’, and ‘non-response’ (ACR20 criteria). Patients starting on ‘remis-
sion’ or ‘non-remission’ states could transit between them or to ‘orthopedic inter-
vention’ (ORT), ‘cardiovascular event – myocardial infarction/stroke’ (CVE), ‘all-
cause death’, ‘cardiovascular death’, and ‘surgery-related death,’ or switch to
second-line (adalimumabMTX or infliximabMTX). Patients initiating on ‘dis-
continuation’ or ‘non-response’ states switched directly to second-line therapy.
Remission (DAS282.6) was considered as effectiveness outcome. Clinical data
were extracted from literature, and costs from Brazilian official databases, pre-
sented in 2012 USD. Univariate sensitivity analyses were performed. A 5% discount
rate was applied annually for costs and benefits. RESULTS: For each 1,000 patients,
244 and 106 were in remission at year 5 for ETNMTX and MTX groups, respec-
tively. The number of [ORT; CVE] was [102; 38] for ETNMTX and [125; 43] for MTX.
Projected treatment costs for ETNMTX and MTX were 54,433,960USD, and
40,175,096USD, respectively. In cost-effectiveness analysis, ETNMTX was the
most effective alternative (incremental effectiveness: 138) and presented an incre-
mental cost (14,258,866USD) with incremental cost-effectiveness ratio of
102,968USD per remission achieved. CONCLUSIONS: Etanercept in ERA treatment
showed to prevent disease progression, with more achieved remissions and
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avoided ORT and CVE, from the public perspective in Brazil, with associated in-
crease costs.
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OBJECTIVES: Blood stem cell mobilization, which is important as a source of he-
matopoietic stem cells for transplantation, is performed using granulocyte colony-
stimulating factor (G-CSF), but is ineffective in around 20% of so called poor mobi-
lizers. Combining G-CSF with plerixafor increases the percentage of successful
mobilizations. The drug has orphan drug status and is approved for lymphoma and
multiple myeloma patients. The objective was to compare the cost-effectiveness of
three available mobilization schemes: i) the use of plerixafor “on demand” (POD)
even during a first mobilization attempt in all patients who show inadequate re-
sponse, ii) the standard use of Plerixafor strictly within a standard re-mobilization
scheme following failure of the first mobilization (SSP), and iii) the standard (re-
)mobilization scheme without Plerixafor (SSNP). METHODS: Decision tree models
were built to compare clinical outcomes and direct costs from the payer’s perspec-
tive in all three strategies. They were populated with efficacy resource use data
from a first-of-a-kind patient registry of all patients with plerixafor administered
(n93) in 6 Czech centres. RESULTS: The success rates and costs for POD, SSP and
SSNP were 94.9% and EUR 5,736, 94.7% and EUR 6,416, and 84.7% and EUR 4,775,
respectively. The direct cost per successfully treated average patient was EUR
6,046, EUR 6,776 and EUR 5,641, respectively. The cost of the first mobilization
attempt with G-CSF was EUR 3,905 per patient. The cost of re-mobilization of a poor
mobilizer was EUR 4,629 with G-CSF only and EUR 13,354 if plerixafor was added.
The total cost of plerixafor used on-demand in the sub-cohort of poor mobilisers
was EUR 13,645. CONCLUSIONS: Plerixafor substantially increases chances of suc-
cess and its use is more cost-effective “on demand” during early mobilization than
in subsequent re-mobilization.
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OBJECTIVES: To evaluate the cost-effectiveness of icatibant [Shire HGT] 30 mg
subcutaneous versus C1-esterase inhibitor concentrate (C1-INH) [CSL-Behring] 20
IU/kg intravenous for moderate to severe attacks of hereditary angioedema (HAE)
types I and II in the UK setting. METHODS: A probabilistic cost-utility model was
developed over a time horizon of 96 h (the duration of a single acute attack). Com-
parisons were made for therapy administered at home and in hospital. Quality-
adjusted life years (QALYs) were estimated by combining the time to onset of
symptom relief with utility weights for the health states before and after onset of
symptom relief. Clinical evidence and other model parameters were identified by
systematic review. An indirect comparison using previously published methods
was conducted. Costs relating to drug acquisition; administration; repeat injec-
tions; monitoring and supportive care; hepatitis A and B vaccinations for C1-INH;
self-administration training; and adverse events were considered. Probabilistic
and univariate sensitivity analyses were conducted. RESULTS: The indirect analy-
sis suggested a non-significant trend towards a reduced time to symptom relief for
icatibant when compared with C1-INH. In the economic analysis, there was a non-
significant inter-treatment difference in estimated QALYs per attack, equivalent to
0.75 quality-adjusted life hours in icatibant’s favour. In the base-case analysis
(SmPC dosing and NHS list price), total costs per attack were estimated as £1,577 for
icatibant and £2,169 for C1-INH; a saving of £592 (95%CI: £394–£715) per attack with
icatibant. CONCLUSIONS: This is one of the first comparative health economic
models presented for HAE. The systematic approach to data identification and
analysis led to successful submissions to SMC and AWMSG in this orphan indica-
tion. The analysis demonstrated that icatibant reduces costs versus C1-INH (20
IU/kg at SmPC dosing) when treating acute HAE attacks in the UK setting.
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OBJECTIVES: To estimate the cost-effectiveness of febuxostat compared with allo-
purinol in the treatment of hyperuricaemia in patients with chronic gout when
urate deposition has already occurred. METHODS: A Markov model was developed
to estimate costs, clinical outcomes, and QALYs for patients with hyperuricaemia
and chronic gout. Febuxostat 80 mg/120 mg as first line therapy (with or without
allopurinol as second line therapy) and as second line therapy (after first line allo-
purinol) was compared to current standard therapy, i.e. allopurinol 300 mg daily
with no second line treatment. A dichotomous sUA response/no response outcome
after the first 3 months of each active treatment was used to decide when patients
switched to a second line treatment. The definition of sUA response was applied
using a target sUA level of  6.0 mg/dL which was based on the latest EULAR
guidelines. Efficacy data (sUA levels) were derived from febuxostat Phase III trials
(APEX, FACT). Unit costs were derived from official tariffs (€2009). 3% discount rate
and 5-year time horizon was applied in the primary analysis. Sensitivity analyses
were performed to assess the impact of variations on all model inputs and sub-
group analyses (patients intolerant to allopurinol, or patients having mild-moder-
ate renal impairment). Analyse was carried out from the National Health System
perspective. RESULTS: The addition of febuxostat in any therapeutic strategy (both
as first-line or second line treatment) is an efficient option, with incremental cost-
effectiveness ratios (ICER) compared with standard allopurinol 300 mg ranging
from 3,800 € to 6,600 €. The cost-effectiveness results show that the two-step two-
drug treatment strategies provide additional QALY benefit over the single-step
single-drug treatment strategies. CONCLUSIONS: Results suggest that febuxostat
is a cost-effective treatment in Spain for the management of hyperuricemia in
patients with gout, showing ICERs far below the commonly cited efficiency thresh-
old in Spain (30,000€/QALY).
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OBJECTIVES: A pharmacogenetic test (PGx) prior to prescribing azathioprine is
available to identify patients at increased risk of dose-limiting side effects (eg.
neutropaenia). This study had two aims (1) to evaluate whether the PGx is a cost
effective use of health care resources and (2) to understand whether it is feasible to
conduct a prospective economic trial of a PGx. METHODS: An economic evaluation
integrated into a prospective, pragmatic, multi-centre (n19) randomised con-
trolled trial (RCT) compared (i) PGx with standard care (SC); 167 patients to (ii) SC
comprising step-wise dose escalation of azathioprine; 166 patients. The perspec-
tive of the UK NHS, with 4-month time horizon, was used to be consistent with the
original RCT (the TARGET study). Individual patient-level data on resource use
(primary care, secondary care, drug-use, monitoring tests) and health status (EQ-
5D) were collected for all recruited patients. Quality adjusted life years (QALYs)
were calculated using UK-population EQ-5D tariffs. Unit costs were collected from
national sources (price year: 2010). GLM regression models estimated incremental
costs and QALYs. Uncertainty in the results was characterised through the use of
non-parametric bootstraps and cost-effectiveness acceptability curves with one-
way sensitivity analysis to explore methodological assumptions. RESULTS: PGx
with SC was £436 (95% CI: -£1064, £119) less expensive but with fewer QALYs
0.00451 (95% CI: -0.01291, 0.00430) compared with only SC. Analysis indicated that
clinicians did not follow azathioprine prescribing recommendations in the PGx
arm, resulting in no difference in the dosage of azathioprine between the two arms
at 4-months (p0.25). Uncertainty in the results was driven by problems associated
with prescribing behaviour as well as low power due to small sample size.
CONCLUSIONS: The analysis found that PGx could be a cost-effective use of re-
sources but key uncertainties remain, driven by the challenge of conducting a
trial-based economic evaluation of a diagnostic PGx.
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OBJECTIVES: To evaluate the cost-effectiveness of ustekinumab for the treatment
of moderate-to-severe plaque psoriasis from the perspective of the public health
care institutions in Mexico.METHODS:A Markov model was developed to simulate
patients with moderate-to-severe plaque psoriasis. Biologic therapies compared
were ustekinumab 45mg every 12 weeks, adalimumab 40mg every two weeks,
etanercept 50mg twice a week and infliximab 5mg/kg every eight weeks. Measured
by the Psoriasis Area and Severity Index (PASI), clinical response was derived from
the latest published meta-analysis. PASI response was translated into QALYs in
two steps: (1) defining the correlation between PASI levels and the Dermatology Life
Quality Index (DLQI); and (2) using a formula to predict utility from DLQI score
derived from a mapping exercise of the DLQI with the EQ-5D. The model considered
expenditure on drugs, monitoring visits, adverse events and inpatient stays. Costs
were obtained from Mexican public institutions. Health and economic outcomes
were estimated over a 10-year time horizon with cycle length of 12 weeks. Cost and
QALYs were discounted at 5% annually. RESULTS: For patients with body weigh
above 60kg, Adalimumab was an extended dominated strategy by ustekinumab.
For these patients, the incremental cost-per-QALY of ustekinumab vs etanercept
was US$19,542, whereas the incremental cost-per-QALY of infliximab vs usteki-
numab was US$87,745. For patients with body weigh below 60kg, infliximab is more
effective and less costly than adalimumab and ustekinumab, while the incremen-
tal cost-per-QALY vs etanercept was US$5,202. CONCLUSIONS: Considering the
GDP per-capita of Mexico in 2010 (US$9,123), and according to the WHO Commis-
sion on Macroeconomics and Health, in patients with body weigh above 60kg
ustekinumab is a cost-effective strategy (3xGDP per-capita /QALY gained); while
in patients with body weigh below 60kg infliximab is a highly cost-effective strat-
egy (1xGDP per-capita/QALY gained). Probabilistic sensitivity analysis results did
not change the conclusions.
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